Parkman Healthcare Partners LLC Purchases 238,747 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Parkman Healthcare Partners LLC boosted its position in Replimune Group, Inc. (NASDAQ:REPL) by 45.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 763,747 shares of the company’s stock after purchasing an additional 238,747 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Replimune Group were worth $8,371,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Arizona PSPRS Trust bought a new position in Replimune Group during the 3rd quarter valued at approximately $834,000. Baker BROS. Advisors LP increased its holdings in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares in the last quarter. Erste Asset Management GmbH purchased a new position in shares of Replimune Group in the 3rd quarter worth about $133,000. Braidwell LP boosted its stake in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock valued at $385,000 after purchasing an additional 6,216 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

REPL has been the topic of several analyst reports. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $17.00.

Replimune Group Stock Performance

Shares of REPL opened at $13.14 on Wednesday. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The stock has a 50-day moving average of $11.98 and a two-hundred day moving average of $10.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a market cap of $899.04 million, a P/E ratio of -4.31 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, research analysts predict that Replimune Group, Inc. will post -2.99 EPS for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.80% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.